In patients with T2DM, the blockade of IL-1 receptor signaling improves glycemic control and the ability to secrete insulin, but not insulin resistance itself, as evaluated by insulin-regulated gene expression in skeletal muscle and serum adiponectin levels [63]. Here, INS is linked to Insulin resistance.